Horizon Discovery, H3 Bio Launch Screening Program for Oncology Targets | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery and H3 Biomedicine today launched SyntheTx, a technology partnership created to provide novel oncology targets and early-stage drug discovery programs to drug manufacturers.

H3 Biomedicine, a Cambridge, Mass.-based biopharmaceutical firm, is the first partner in the program. Additional partners will be sought in the first 12 to 18 months of the program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variant protective against Alzheimer's disease, effect of whole-genome duplication on methylation in rice, and more.

Genome editing is also bringing up questions when applied to farm animals, the New York Times reports.

Through a transcriptome study, researchers home in on the activity of inflammation-linked genes in chronically lonely people.

Determining who is and is not an author and where a researcher should fall on a list of authors can be a tricky task, Nature News writes.

Sponsored by
Agilent Technologies

This online seminar will discuss a metagenomic assay to identify viruses and other pathogenic microorganisms in human tumor samples, with the aim of gaining a more comprehensive understanding of the role of the microbiome in cancer development and treatment.